Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289492 · ClinicalTrials.gov registry record · Phase 1
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by iTeos Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05289492 is a Phase 1 study that was terminated before completion, run by iTeos Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT05289492, a Phase 1 study, was terminated before completion, sponsored by iTeos Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Interventions
- DRUG Dexamethasone
- DRUG Iberdomide
- DRUG EOS884448
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2023-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05289492
The ClinicalTrials.gov registry entry for NCT05289492 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is iTeos Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT05289492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05289492 about?
NCT05289492 is a clinical study titled "Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma". This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with...
What is the current status of trial NCT05289492?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-05-01. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT05289492?
The interventions under investigation include: Dexamethasone (DRUG), Iberdomide (DRUG), EOS884448 (DRUG).
Who is sponsoring clinical trial NCT05289492?
This trial is sponsored by iTeos Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.